TVTX ▼ -0.0% - Travere Therapeutics, Inc. $TVTX Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis Travere Therapeutics received a notice of allowance from the U.S. Patent and Trademark Office for a patent application covering methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis, which extends intellectual property protection for the therapy. The stock was flat on the day, suggesting the market had already priced in the patent approval or saw limited near-term commercial impact from the development. 23-SEP-2026 07:00 AM ET